Overview
Primary open-angle glaucoma is a chronic, progressive, irreversible, usually bilateral disease of the eye with an insidious onset.
It is most often characterized by optic nerve damage, defects in the retinal fiber layer and subsequent visual field loss in the absence of underlying ocular disease or congenital abnormalities.
It is generally asymptomatic until it has caused a significant loss of visual field.
Occasionally, patients with very high intraocular pressure may complain of nonspecific headache, discomfort, intermittent blurring of vision or even halos caused by corneal edema.
The goal of primary open-angle glaucoma treatment is to preserve the quality of life and maintain the visual status of the patient.
Topical glaucoma preparations are used to either decrease aqueous humor production (adrenergic agonists, beta blockers, carbonic anhydrase inhibitors) or increase aqueous humor outflow (adrenergic agonists, parasympathomimetics, prostaglandins, Rho kinase inhibitor).
For further information regarding the management of Primary Open-Angle Glaucoma, please refer to Disease Algorithm for the Treatment Guideline chart.
It is most often characterized by optic nerve damage, defects in the retinal fiber layer and subsequent visual field loss in the absence of underlying ocular disease or congenital abnormalities.
It is generally asymptomatic until it has caused a significant loss of visual field.
Occasionally, patients with very high intraocular pressure may complain of nonspecific headache, discomfort, intermittent blurring of vision or even halos caused by corneal edema.
The goal of primary open-angle glaucoma treatment is to preserve the quality of life and maintain the visual status of the patient.
Topical glaucoma preparations are used to either decrease aqueous humor production (adrenergic agonists, beta blockers, carbonic anhydrase inhibitors) or increase aqueous humor outflow (adrenergic agonists, parasympathomimetics, prostaglandins, Rho kinase inhibitor).
For further information regarding the management of Primary Open-Angle Glaucoma, please refer to Disease Algorithm for the Treatment Guideline chart.
